Agoracom Blog

American Creek $AMK.ca: Interview with Ken Konkin Concerning Potential World Class Deposit in Golden Triangle $TUD.ca $SII.ca $GTT.ca $AFF.ca $SEA.ca $SA $PVG.ca

Posted by AGORACOM at 2:21 PM on Thursday, December 5th, 2019

Ken Konkin Discusses the Goldstorm Deposit at Treaty Creek (including recent outstanding drill results like 0.725 g/t over 838.5m), it’s Potential, and 2020 Development Plans

https://mailchi.mp/bf6603f1de9b/ken-konkin-discusses-the-goldstorm-deposit-treaty-creek-its-potential-and-2020-development-plans-in-a-brand-new-interview?e=d81c2ca55c

https://www.commodity-tv.com/play/tudor-gold-the-next-major-discovery-in-the-golden-triangle/

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/682/49176_99c64899f4a48b79_001.jpg

About American Creek

American Creek is a Canadian junior mineral exploration company with a strong portfolio of gold and silver properties in British Columbia.

Three of those properties are located in the prolific “Golden Triangle”; the Treaty Creek and Electrum joint venture projects with Tudor Gold/Walter Storm as well as the 100% owned past producing Dunwell Mine.

The Treaty Creek Project is a Joint Venture with Tudor Gold owning 60% and acting as operator. American Creek and Teuton Resources each have 20% interests in the project. American Creek and Teuton are both fully carried until such time as a Production Notice is issued, at which time they are required to contribute their respective 20% share of development costs. Until such time, Tudor is required to fund all exploration and development costs while both American Creek and Teuton have “free rides”.

More information about the Treaty Creek Project can be found here: https://americancreek.com/index.php/projects/treaty-creek/home

A drill program is also ongoing on American Creek’s 100% owned Dunwell Mine property located near Stewart. More information can be found here: https://americancreek.com/index.php/projects/dunwell-mine

The Corporation also holds the Gold Hill, Austruck-Bonanza, Ample Goldmax, Silver Side, and Glitter King properties located in other prospective areas of the province.

For further information please contact Kelvin Burton at: Phone: 403 752-4040 or Email: [email protected]. Information relating to the Corporation is available on its website at www.americancreek.com.

Hub on Agoracom
  FULL DISCLOSURE: American Creek is an advertising client of AGORA Internet Relations Corp.

New Age Metals $NAM.ca – #Palladium zooms past $1,860/oz $WG.ca $XTM.ca $WM.ca $PDL.ca $GLEN

Posted by AGORACOM-JC at 12:42 PM on Thursday, December 5th, 2019

SPONSOR: New Age Metals Inc. The company owns one of North America’s largest primary platinum group metals deposit in Sudbury, Canada. Updated NI 43-101 Mineral Resource Estimate 2,867,000 PdEq Measured and Indicated Ounces, with an additional 1,059,000 PdEq Ounces in the Inferred. Learn More.

Palladium zooms past $1,860/oz

  • Palladium was up 0.3% at $1,845.80 an ounce, after hitting a new high of $1,861.71 earlier in the session.
  • The metal has been breaking records daily since Nov. 25.

“Palladium positioning is slightly counter-intuitive to the price action, implicitly confirming heavy OTC interest from the long side,” INTL FCStone analyst Rhona O’Connell said in a note. “After weak longs were shaken out in early November another push to the upside is now approaching resistance from the uptrend.”

Concerns that supply of the metal used in car exhaust systems could run out has helped to lift prices by more than 47% this year alone, despite a weakening auto sector.

Silver shed 0.4% to $16.95 an ounce and platinum gained 0.4% to $903.51.

Source: https://www.cnbc.com/2019/12/02/gold-markets-us-dollar-china-economy-in-focus.html

LOMIKO Metals $LMR.ca – Imerys and Lomiko Step Up Battery Materials Development As The Decade of the Electric Vehicle Revolution Begins $CJC.ca $SRG.ca $NGC.ca $LLG.ca $GPH.ca $NOU.ca

Posted by AGORACOM at 9:20 AM on Thursday, December 5th, 2019
  • Imerys and Lomiko Step Up Battery Materials Development As The Decade of the Electric Vehicle Revolution Begins

Lomiko Metals Inc. (TSX-V: LMR, OTC: LMRMF, FSE: DH8C) (Lomiko or the “Company”) has identified spherical graphite production as a key goal in plans to supply graphite anodes for Electric Vehicles (EV) Li-ion battery mega-factories in the North American market as  highlighted  in Lomiko’s  July 16th, 2019 release.  Testing for spherical graphite is to be included in the upcoming Lomiko Preliminary Economic Assessment (PEA) which is planned for the La Loutre graphite project located in Quebec, Canada. 

The development of a strategy that identifies a way to create value-added products is necessary to establish a long-term, profitable business model prior to extensive capital outlay and is crucial to the success of the company.  A large multinational conglomerate, Imerys Carbon and Graphite has also been working on new developments in the graphite space with innovative products for the EV Industry.

Imerys Graphite & Carbon has a strong history in the production of high-quality natural and synthetic graphite powders, conductive carbon blacks and water-based graphite dispersions with the parent company posting €4.6 billion in revenue and approximately 17,000 employees worldwide.

Imerys Graphite & Carbon’s fully owned natural graphite mine is located about 250 km north-west of Montréal, Canada, in the small town of Lac-des-ÃŽles [53 km north of Lomiko’s La Loutre Graphite Property]. Operations started in 1989. There, graphite ore is mined and refined into high-quality graphite products of various sizes and purities. These graphite concentrates are directly sold to various applications or further processed in its Terrebonne, Quebec plant [near Montreal].  In a news release dated November 18, 2019, Imerys stated:  

“New developments in automotive and in the consumer electronics markets are driving a need for improved performance of lithium-ion batteries in diverse operating conditions. QX products [graphite additive tradename] enable fast kinetics during charging and can significantly improve the performance of active materials.”

“We are at the beginning of the battery materials bull market with 100+ Lithium-ion, mega-factories built or scheduled to be built worldwide,” said Lomiko’s CEO A. Paul Gill.   â€œLomiko sees a tremendous opportunity in creating a stable and integrated North American value supply chain for North American EV manufacturers.  This opportunity represents a significant increase of confidence to the Quebec government, Lomiko, and other companies to see Imerys step into the EV field despite being close to closing their twenty-year operation at the Lac-des-ÃŽles facility.”

Graphite Sector Analysis

The price for 95% C (purity), 15 microns Spherical Graphite is $2,700-2,800 USD/tonne, far above the price of other forms of graphite as indicated by the Industrial Minerals.  Lomiko’s Preliminary Economic Assessment (PEA) will include costs and the potential market for this key product.  In order to start the PEA, Lomiko must first deliver its second resource prepared in compliance with NI 43-101 Regulations from La Loutre.

On November 4, 2019, Imerys announced: [Natural and synthetic graphite] subject to general inflationary pressures and will, therefore, be subject to some price increases to reflect those inflation effects.

On October 18, 2019, A recently opened mine in Mozambique owned by Syrah Resources, which primarily produces 94% C, -100 mesh material since 2017, significantly reduced their workforce and cut production targets for 2020.

The production cut will likely curtail the supply of natural flake graphite supporting a general conclusion that an uptrend in graphite prices may be imminent after a multi-year low in demand and price.

For more information on Lomiko Metals, review the website at www.lomiko.com, contact A. Paul Gill at 604-729-5312 or email: [email protected].

On Behalf of the Board,

“A. Paul Gill”

Chief Executive Officer 

We seek safe harbor. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

Attachment

A. Paul Gill
Lomiko Metals Inc. (TSX-V: LMR)

Empower Clinics $CBDT.ca – Researchers Leverage #CBD Medical Properties to Fight a Plethora of Ailments $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Posted by AGORACOM-JC at 6:22 PM on Wednesday, December 4th, 2019

SPONSOR:

Why Empower Clinics

  • A leading owner/operator of physician staffed health and pain management clinics.
  • Patient database of over 165,000 patients 
  • Platform generating $1.4M USD (9 months ending Sept. 30, 2019)
  • Proprietary technology platforms including Electronic Health Records portal and e-Commerce for CBD product distribution
  • Recently launched CBD extraction facility
  • First extraction system capacity = 6,000 Kg per year.
  • CBD based products are poised to be a $20B global industry by 2022
  • Medical cannabis is poised to be a $100B global industry by 2025

——————

Researchers Leverage CBD’s Medical Properties to Fight a Plethora of Ailments

  • Over the past year, demand for cannabidiol, or CBD, has been increasing at an exponential pace.
  • In particular, the U.S. experienced massive growth in CBD sales after it passed the Farm Bill in late 2018, legalizing the commercialization of hemp, which CBD is derived from.
  • CBD is the active chemical found within the hemp plant, which falls under the cannabis family

NEW YORK, Dec. 4, 2019 — Over the past year, demand for cannabidiol, or CBD, has been increasing at an exponential pace. In particular, the U.S. experienced massive growth in CBD sales after it passed the Farm Bill in late 2018, legalizing the commercialization of hemp, which CBD is derived from. CBD is the active chemical found within the hemp plant, which falls under the cannabis family.

Similarly, marijuana also falls under the cannabis family, but marijuana and hemp are widely different in their biological makeup, as marijuana’s active chemical is THC, which is generally known to induce psychoactive effects. Meanwhile, CBD does not cause mind-altering effects but instead stimulates relaxation. Moreover, extensive clinical trials have also concluded that CBD can be effectively used in healthcare to treat a variety of medical conditions.

Consequently, many countries began to move towards legalizing CBD because of its versatile uses. For instance, researchers have boasted that CBD can treat symptoms associated with cancer, chronic pain, Alzheimer’s, multiple sclerosis, and epilepsy. However, in the U.S., there is currently only one CBD-based drug approved: Epidiolex. Epidiolex is used to treat Lennox-Gastaut and Dravet syndromes, which are two rare epileptic disorders that occur early in adolescence. And while the U.S. has only approved CBD for epilepsy-related conditions, other countries have legalized CBD-based drugs to treat other serious conditions such as HIV/AIDS, depression, and even withdrawal from opioid drugs.

Nevertheless, it is important to remember that the CBD industry is still in its infancy stage due to the lack of research authenticating the benefits of the compound. But researchers around the world are engaged in clinical trials to rectify this and prove the efficacy of CBD while promoting it as a next-generation medical treatment. According to data compiled by Grand View Research, the global cannabidiol market was valued at USD 1.34 Billion in 2018 and is expected to expand at a CAGR of 32.6% over the forecast period from 2019 to 2025.

Overall, there are hundreds of studies being conducted to evaluate the efficacy of CBD. Notably, researchers are advancing studies to further promote the use of the CBD for Parkinson’s treatment. Currently, the research on CBD for Parkinson’s is very limited and most studies are likely small-scale trials. However, the handful of studies that have been conducted suggest that CBD can have positive effects when dealing with nonmotor symptoms. According to Healthline, several studies have hinted that CBD can be used to treat tremors, psychosis, and improve the overall quality of life for some patients. For example, a small scale study suggested that CBD may help ease muscle movements, while another study discovered that CBD reduced the severity of individuals’ suffering from psychotic symptoms.

Meanwhile, another study suggested that CBD can help suppress sleep disturbances such as vivid dreams, nightmares, or movement. Additionally, several researchers even believe that CBD can ultimately be used to prevent Parkinson’s disease, even as there is currently insufficient data on the use of CBD on humans to prevent Parkinson’s. Nevertheless, researchers are actively evaluating the effects of CBD on protecting the human brain. And while research on CBD is limited, the small-scale results are highly promising.

As such, CBD clinical trials are anticipated to accelerate in the shortcoming future. “The work to date on marijuana and cannabinoids has given promising but conflicting signals,” said Rachel Dolhun, MD, Vice President, Medical Communications at The Michael J. Fox Foundation for Parkinson’s Research. “This therapy may represent a future treatment option for PD, but the correct dose and formulation are not clear, full side effects and drug interactions are unknown, and benefits have not been rigorously determined. Future studies should be large and well designed to provide clear data on the safety and efficacy of marijuana and cannabinoids in Parkinson’s.”

Source: https://www.ptcommunity.com/wire/researchers-leverage-cbds-medical-properties-fight-plethora-ailments

CardioComm Solutions $EKG.ca – How #Mhealth apps are providing solutions to the healthcare market’s problems $ATE.ca $TLT.ca $OGI.ca $ACST.ca $IPA.ca

Posted by AGORACOM-JC at 3:09 PM on Wednesday, December 4th, 2019

SPONSOR: CardioComm Solutions (EKG: TSX-V) – The heartbeat of cardiovascular medicine and telemedicine. Patented systems enable medical professionals, patients, and other healthcare professionals, clinics, hospitals and call centres to access and manage patient information in a secure and reliable environment.

How mHealth apps are providing solutions to the healthcare market’s problems

  • Mobile health is the monitoring and sharing of health information via mobile technology – such as wearables and health tracking apps.
  • The use of mobile devices and wireless technology to monitor symptoms and deliver care allows physicians to make diagnoses quicker and with fewer errors. 

By: Alicia Phaneuf

Today’s consumers don’t want to solely rely on yearly physicals or scattered drop-in appointments to monitor their health – they are seeking more individualized control over the way healthcare is accessed so that they can analyze personal health data and talk to healthcare professionals at all times.

By embracing mobile health, or mHealth, patients are able to keep track of their own health data in real time and inform healthcare providers of any abnormalities at the push of a button.  

What is mHealth (mobile health)?

Mobile health is the monitoring and sharing of health information via mobile technology – such as wearables and health tracking apps. The use of mobile devices and wireless technology to monitor symptoms and deliver care allows physicians to make diagnoses quicker and with fewer errors. 

And as tech giants like Apple and Google continue pushing their way into healthcare, mHealth will likely grow in popularity.

mHealth vs telehealth

Telehealth uses technology to extend the reach of healthcare professionals beyond traditional clinical settings. It’s a broad term describing how the healthcare market is taking advantage of digital development to enable remote care.

Comparatively, mHealth is a subset of telehealth, referring specifically to the use of mobile technology to inform and educate consumers on healthcare. It uses mobile devices to monitor patients’ exercise, heart rate, and medication adherence.

Examples of different types of mHealth apps

Mobile health is gaining steam among consumers as Apple and Google continue to offer an array of mHealth applications on their app stores; there were more than 318,000 mHealth apps available for download worldwide as of November 2017. Some of the most common categories of mHealth apps include: 

  • Diabetes 
  • Pregnancy 
  • Weight loss 
  • Chronic illness 

Benefits of mHealth app solutions

Stakeholders across the healthcare industry are looking to tap into the mHealth opportunity as Mobile health applications are beginning to integrate electronic health records (EHRs) and other wearable tech devices

According to Business Insider Intelligence, nearly half of all mHealth app publishers integrate with EHRs in order to provide a detailed representation of a patient’s health or medical history. Stakeholders across the healthcare industry are looking to tap into the mHealth opportunity. Business Insider Intelligence

Healthcare providers could reduce appointment costs by taking advantage of mHealth applications – which lowers the risk of patient rehabilitation. Instead of staying in a healthcare facility post surgical discharge, patients could utilize mHealth apps for recovery instructions and medication reminders. 

Payers – which handle the financial aspects of healthcare – can also capitalize on mHealth cost benefits. According to a 2018 Leavitt Partners report, clinical care only accounts for 20% of health, and social determinants account for the remainder. 

Health insurance providers could develop mobile apps that provide consumers with health education and send reminders to purchase healthy food – keeping patients largely responsible for their own healthcare.

mHealth industry trends & technologies

One concern consumers have regarding mHealth solutions has to do with data-sharing practices among multiple technologies and applications. According to Business Insider Intelligence, 79% of 24 top-rated mHealth apps shared user data with 55 entities, like app developers and third parties. 

Despite privacy concerns however, Business Insider Intelligence predicts that as big tech companies like Apple and Samsung continue to generate their own health features in smartphones, the adoption of mHealth apps will continue to grow.

In fact, Apple grew wearable revenue 42% year-over-year in 2018 and has the potential to hit $15 billion in healthcare-related revenue by 2021. 

Business Insider Intelligence’s Digital Health Ecosystem Report explores digital disruption in healthcare, detailing how technologies like mobile health apps are reshaping the industry. The report outlines the role of major players in healthcare from payers to consumers – explaining how they’re all being affected amid the  industry’s digital awakening.

Source: https://www.businessinsider.com/mhealth-apps-definition-examples

SPONSOR: BetterU Education Corp. $BTRU.ca – #Edtech Startup Digital Gurukul Rolls Out Blockchain-Powered Diplomas $ARCL $CPLA $BPI $FC.ca

Posted by AGORACOM-JC at 12:21 PM on Wednesday, December 4th, 2019
SPONSOR:  BetterU Education Corp. aims to provide access to quality education from around the world. The company plans to bridge the prevailing gap in the education and job industry and enhance the lives of its prospective learners by developing an integrated ecosystem. Click here for more information.

Edtech Startup Digital Gurukul Rolls Out #Blockchain – Powered Diplomas

  • The startup has partnered with Germany-based Certif-ID
  • Receivers would not need additional devices to view the diploma
  • The company was in talks to raise $5 Mn for 10% stake

Indore-based Edtech startup, Digital Gurukul, has partnered with German tech networking company Certif-ID to roll out blockchain-powered certificates and Will allow employers to access the diplomas of applicants from any geographical locations.

By integrating blockchain with certificates and diplomas, Digital Gurukul is eliminating the need to send or physically present degrees. The people receiving these diplomas would not require any additional software or special equipment. The parties can simply view the diploma by scanning the QR code which is printed on the certificate.

All the students graduating from Digital Gurukul will not be provided with the blockchain-powered diploma to make the job and college hunting much simpler and seamless. The diploma will include information like educational qualifications, portfolio, projects and attendance. Dr. Raj Padhiyar, director of Digital Gurukul, said the adoption of Blockchain Technology is still in its infancy in the education industry. “But we believe it can help make the Indian education system more dependable and trustworthy,” he added.

Founded in 2014 by Padhiyar, Digital Gurukul has been awarded the “Asia’s Best Digital Marketing Institute”​. The company educates students regarding digital marketing and its various aspects. Digital Gurukul aims to have trained over 6K students by March 2020, which also includes some prominent names like Wittyfeed cofounder Parveen Singhal and Renaissance Indira Group of Institute’s founder chairman Swapnil Kothari.

In August 2019, Digital Gurukul announced that it was in talks with some investors to raise $5 Mn for a 10% stake. The company planned to use the funding to expand its operations to over 40 offline learning centres, invest in content and programmes and aid its international expansion.

The company’s official statement also added that it is planning to venture into the Middle East and Southeast Asian markets. The company, in its previous press release, also claimed that it has received over 120 franchisee requests across Asia. Digital Gurukul also has associations with reputed Indian institutes like IIM Indore, IIT Indore, NMIMS and Welingkar Institute, among others.

According to DataLabs by Inc42, Indian edtech startups received a funding of approximately $700 Mn in 2018, noting an 85% hike from the $375 Mn funding raised in 2017. Interestingly, of the $375 Mn raised, BYJU’s had raised $230 Mn in 2017.

The report also notes that only 7% of the 3,500 startups operating in the edtech space are funded, as of 2018. The Datalabs by Inc42 also highlights that 182 edtech startups generated funding of $1.34 Bn between 2014 to 2018. Of these, only 52 startups, making up for 28.5%, received more than $1 Mn in funding which amounts to $1.3 Bn. Meaning that the 52 startups comprised  99% of the total funding in the period.

Source: https://inc42.com/buzz/edtech-startups-digital-gurukul-rolls-out-blockchain-powered-diplomas/

ThreeD Capital Inc. $IDK.ca – 5 #Crypto Projects That Crushed It in 2019 #Bitcoin #Ethereum $HIVE.ca $BLOC.ca $CODE.ca

Posted by AGORACOM-JC at 11:46 AM on Wednesday, December 4th, 2019

SPONSOR: ThreeD Capital Inc. (IDK:CSE) Led by legendary financier, Sheldon Inwentash, ThreeD is a Canadian-based venture capital firm that only invests in best of breed small-cap companies which are both defensible and mass scalable. More than just lip service, Inwentash has financed many of Canada’s biggest small-cap exits. Click Here For More Information.

5 Crypto Projects That Crushed It in 2019

  • Crypto startups that shrugged off bearish market conditions, community apathy and industry in-fighting, and focused on shipping clean code and great products.
  • There’s a lot of noise in the cryptosphere, but the following projects cut through it like a knife, delivering original solutions with genuine utility.

As 2019 nears its apex, it’s time to take a look back at the projects that crushed it this year. Crypto startups that shrugged off bearish market conditions, community apathy and industry in-fighting, and focused on shipping clean code and great products. There’s a lot of noise in the cryptosphere, but the following projects cut through it like a knife, delivering original solutions with genuine utility. Having killed it all year, you wouldn’t bet against this quintet doing it all over again in 2020.

  1. LiquidApps

EOS scaling project LiquidApps emerged out of nowhere to garner industry-wide plaudits as 2019 reached its crescendo. A lot of this was due to the success of its DAPP Network, which demonstrated that it’s possible to provision off-chain/sidechain scaling without compromising on decentralization. The DAPP Network’s vRAM enables EOS dApp developers to access cheap virtual storage, giving them the ability to scale their decentralized applications without being stung by prohibitive resource costs. That alone would be enough to sustain most crypto projects for a year, but LiquidApps accompanied this breakthrough with a tool for seamlessly onboarding new dApp users, another for linking blockchains into a single dApp, and an oracle service. Impressive stuff.

  1. Remme

Distributed Public Key Infrastructure (PKI) project Remme boasts one of the hardest working teams in crypto. After realizing that its PKI-enabled blockchain simply wouldn’t cut it on Hyperledger Sawtooth, the Remme team made the difficult decision to switch chains deep into the project, transitioning to the EOSIO codebase and rolling out its testnet. Rather than letting this throw them off their stride, Remme has charged ahead with its mainnet launch, taking time out to propose improvements to EOSIO where errors were encountered in the codebase, and fine-tuning the workings of its custom Block Producer program.

This year, Remme also succeeded in onboarding hundreds of enterprises to Keyhub, its all-in-one platform for managing SSL/TLS certificates. With its mainnet just weeks away, 2020 is shaping up to be a big year for the Ukrainian blockchain startup.

  1. Matic Network

It would be impossible to review 2019’s biggest breakout successes without including Matic. While the meteoric rise of its token in recent weeks, following its April IEO on Binance, has kept investors happy, that’s merely a symptom of its success in becoming the industry’s blockchain scaling solution of choice.

While Ethereum remains mired in ETH problems, Matic has emerged as a genuinely scalable and production-ready chain that can take the strain. Its adaptation of Plasma enables instant on-chain payments and transactions, making it suitable for everything from dApps to DEXs. Dozens of crypto projects have announced their migration to Matic Network including a number specializing in NFTs such as Battle Racers. In 2020, expect this trickle to transform into a torrent as crypto projects migrate en masse.

  1. Chainlink

If there’s any token, outside of exchange tokens, that investors wish they’d stacked up on in January, it’s LINK. Up 570% in 12 months, LINK will go down as one of 2019’s best buys. As with Matic, however, focusing on price misses out on the broader story. Much of Chainlink’s success comes down to mastering the other P – partnerships. This year, crypto and non-crypto businesses alike rushed to team up with Chainlink, utilizing the smart contract and oracle network for connecting off-chain data feeds and enabling tamper-proof inputs and outputs.

With names such as SWIFT, Google, Gartner, and IC3 all working with Chainlink, the project founded by Sergey Nazarov has become the first crypto startup to transcend the industry and embed itself in the broader business world.

  1. Synthetix

Warranting the accolade of most innovative defi project of 2019, Synthetix is a smart solution whose best is yet to come. Decentralized synthetic assets have long been the holy grail of many decentralized finance advocates, unlocking the ability to permissionlessly trade commodities, forex and cryptocurrency on DEXs. Synthetix is the first project to realize this goal through its pioneering use of ‘synths,’ tokens that provide exposure to assets such as gold, TESLA stock, and AAPL, without liquidity limitations. Up an incredible 1,715% to date, despite being absent from tier one exchanges, the SNX token looks like it has more room to grow – as does the Synthetix Network it powers.

Source: https://www.newsbtc.com/2019/12/03/5-crypto-projects-that-crushed-it-in-2019/

PRIMO Nutraceuticals Inc. $PRMO.ca – Demand For Hemp, #CBD Oil Could Result In A Christmas Tree Shortage $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 11:08 AM on Wednesday, December 4th, 2019

SPONSOR:  PRIMO NUTRACEUTICALS INC. (CSE: PRMO) (OTC: BUGVF) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) provides strategic capital to the thriving cannabis cultivation sector through ownership and development of commercial real estate properties. The company also offers fully built out turnkey facilities equipped with state-of-the-art growing infrastructure to cannabis growers and processors. Click here for more info.

Demand For Hemp, CBD Oil Could Result In A Christmas Tree Shortage

  • The festive season has already begun! The US market is filled with Black Friday sales and it’s the merriest time of the year. 

By: Daniel Perry

But what’s interesting is the recent news that came from Texas about Christmas trees. Retailers are claiming Christmas trees might get sold out early in December as farmers are inclining towards cash-growing crops like hemp that is used to derive CBD oil- a potent and promising substance. 

Hemp has been trending in the US consumer market since December 2018 when the federal government legalized hemp. Companies have joined the CBD bandwagon offering numerous products ranging from CBD topicals, oils, creams, tincture, bath bombs, gummies, isolate, and what not! 

According to the retailers, the most healthy and big trees usually get sold out early in the festive season, right around Thanksgiving. With the shortage of Christmas trees this year, it is recommended for Texans to book their trees as soon as possible. 

With the inception of legal hemp farming, more and more farmers are exploring the CBD industry and investing their time in growing a cash crop with higher returns. Companies and big cooperation firms scout hemp for their CBD products from such farmers. Hemp is being considered as one of the most profitable crops of the year, as it is sold off at a much higher price as compared to other crops. 

The hemp industry has grown multifold over the past one year with CBD oil as one of its main products. Cannabidiol is a popular ingredient now available in skincare products with promises of increasing elasticity, promoting cell renewal and acting as an anti-aging compound. The cannabis-based beauty products are predicted to grab a piece of the $167 billion market.

Celebrities are touting CBD for its benefits, including Jennifer Aniston, Olivia Wilde, Busy Phillips, and the beauty mogul Kim Kardashian West. Even famous athletes such as Mike Tyson, David Wells, and KC Deane are endorsing CBD brands with products that promise faster recovery from accidents and a good healthy lifestyle overall. 

What Makes CBD So Popular?

CBD or cannabidiol is a hemp-derived substance that has anti-inflammatory, anti-oxidant and stress-relieving properties. Many people have touted CBD for its health benefits such as relieving stress, anxiety, depression, insomnia, back pain, acute ache, muscle injuries, ligament ruptures, arthritis, etc. It is also a potent drug in alleviating the symptoms of life-threatening ailments like cancer, epilepsy, Alzheimer’s and Tourettes. 

The US Food and Drug Administration has approved a cannabis-based medicine named Epidiolex, an oral solution that is used to treat two rare and severe forms of epilepsy- Dravet syndrome and Lennox Gastaut syndrome. These forms of epilepsy are most commonly found in children and experience numerous seizures that affect their overall growth. 

Cannabidiol is non-psychoactive in nature which means it does not produce any harmful mind-altering chemicals, like THC. THC or tetrahydro cannabidiol is the psychoactive component found in marijuana and its derivate plants that is responsible for the ‘high’ that people experience while smoking weed or hemp. It tends to produce a euphoric feeling which can dramatically affect mental health and might even cause permanent mental disorders. 

According to federal regulations, the maximum amount of THC per unit is 0.3%. This limit determines whether a cannabis-based product is safe for consumption or not. Any product containing higher than 0.3% per unit is marked as illegal and can be confiscated by enforcement officials. 

Recently, the FDA started sending out warning letters to companies that promote their cannabis-based products with medicinal promises or as an alternative to licensed medication. The FDA says that there’s a lot of research and background work that needs to be done in the field of cannabis, and promoting cannabis-based products without any relevant study or information is plainly misleading consumers. 

The agency warns customers to thoroughly read and be aware of the effects a cannabis-based product might have before they buy one. Also, it is recommended to buy only from licensed stores as their products are clinically tested, approved and safe for use.

Source: https://thecannabisradar.com/christmas-tree-shortage/7982/

INTERVIEW: PyroGenesis $PYR.ca Numbers Speak For Themselves; $29.5M Backlog + $13.5M Aircraft Carrier Contract Imminent $LMT $RTN $NOC $UTX $HPQ.ca $DDD.ca $SSYS $PRLB

Posted by AGORACOM-JC at 10:28 AM on Wednesday, December 4th, 2019

“These results signal the beginning of the long-awaited breakout that we have been anticipating…’  These are the words of PyroGenesis CEO, Peter Pascali, and they are backed up by Q3 results that included a 91% increases in revenue and a 492% increase in signed contracts that are now in backlog to the tune of $29.5M, thanks to a monster contract win in October.  

If that wasn’t enough, after already having sold two plasma torch based systems to the US Navy for installation on two aircraft carries, the Company has already been advised by the US Navy that 2 more orders are coming for two more aircraft carriers to the tune of $13.5M.  

Even the Head of TSX Venture noticed the results on Linkedin recently:  

If you are just discovering PyroGenesis (PYR:TSXV) then grab your favourite drink and watch this powerful video …. or listen in via podcast when you want to tune out the world and learn about an incredible company.

Applied BioSciences $APPB: Announces Strategic Shift to Fully Focus on BioPharma Division $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 8:46 AM on Wednesday, December 4th, 2019
  • BioPharma division is focused on the development and commercialization of novel therapeutics that target the endocannabinoid system (ECS)
  • BioPharma Division focus unlocks opportunities for non-dilutive capital to fund high-value pipeline
  • Company seeking to spin-off Applied Products division comprised of a portfolio of consumer, animal health, women’s health and sports medicine CBD products
  • Majority owned subsidiary, Trace Analytics, in late-stage discussions for a strategic transaction, expected close to year end 

Applied BioSciences Corp. (OTCQB:APPB) (“Applied” or the “Company”), today announced its strategic corporate shift to fully focus all initiatives and resources on its BioPharma division and the development of science-driven biopharmaceuticals that target the endocannabinoid system.

Through its Applied Products division, the Company currently develops multiple brands offering high quality health and wellness CBD products that conform to the highest regulatory standards and markets through established channels in the US. To date, the Applied Products business unit has seen robust year-over-year increase in top-line revenue. At this time and with the understanding that to be successful in the lucrative yet dynamic and very competitive consumer CBD space would require additional resources and capital allocations, the Applied Board has made the strategic decision to allocate all resources moving forward to the BioPharma business unit.

“After careful consideration, the Board has made the strategic decision that it is in the best interest of the Company and our shareholders, to spin off our consumer-facing CBD business, Applied Products. We believe that this streamlined corporate development pathway will unlock opportunities for non-dilutive capital to expand and advance our pipeline of novel therapeutics addressing areas of high value indications where there remain significant unmet needs,” commented Dr. Raymond Urbanski, Chief Executive Officer of Applied. “Both our Trace Analytics and Products business units represent promising investment opportunities and we are confident that we will be able to identify the right partners to give each unit the proper share of voice in this competitive field.”

“Moving forward we see great potential in our growing BioPharma pipeline. We look forward to continue building momentum and establishing Applied BioPharma as a leader in the development and commercialization of innovative therapeutics that target the endocannabinoid system,” added Dr. Urbanski.

To date, the Applied BioPharma division has developed partnerships with leading academic and research institutions and has exclusively licensed patented, synthetically derived small molecule candidates which target the endocannabinoid (ECS) G-protein coupled receptors (GPCRs) e.g., the cannabinoid receptor 1 and cannabinoid receptor 2, for the treatment of metabolic diseases (type 2 diabetes, obesity, fatty liver disease) and inflammation (pulmonary inflammation, optic nerve inflammation following traumatic brain injury and ischemic/reperfusion injury such as acute kidney injury post-transplant and acute myocardial infarction (heart attack).

The Company’s growing pipeline is comprised of selective CB1 and CB2 agonist, inverse agonist and antagonists utilizing multiple scaffolds and state-of-the-art medicinal chemistry across several academic centers and institutions. Applied expects to advance the first of its preclinical programs into open INDs throughout 2020 and its lead clinical program into a Phase 1 study in early to mid-2020.

The Company is actively advancing and seeking additional in-license opportunities with the goal of developing an industry-leading pipeline of endocannabinoid system-targeted drug candidates that address significant unmet needs across a wide range of therapeutic areas.

About Applied BioSciences Corp.

Applied BioSciences is a vertically integrated company focused on the development and commercialization of novel, science-driven, synthetic cannabinoid therapeutics / biopharmaceuticals that target the endocannabinoid system to treat a wide-range of diseases across multiple therapeutic areas. We also deliver high-quality consumer and OTC THC-free CBD products that promote overall health and wellbeing as well as state-of-the-art testing and analytics capabilities to our customers. For more information, visit appliedbiocorp.com and connect with the Company on Twitter, Facebook and LinkedIn.